1 Department of Paediatrics, University Hospital of North-Norway, N-9038 Tromsø; 2 Department of Paediatrics, Institute of Clinical Medicine, University of Tromsø, Tromsø; 3 Department of Microbiology and Virology, Institute of Medical Biology, University of Tromsø, Tromsø; 4 Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo; 5 Department of Paediatrics, National Hospital, Oslo; 6 Department of Microbiology, National Hospital, Oslo, Norway
Received 16 July 2004; returned 26 August 2004; revised 8 September 2004; accepted 11 September 2004
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials and methods: A total of 180 isolates from 148 patients collected in a single neonatal unit over a 12 year period were examined for susceptibility to gentamicin, tobramycin, netilmicin, amikacin and arbekacin by Etest and/or disc diffusion. AME genes were detected by PCR.
Results: The overall non-susceptibility rates to gentamicin, tobramycin, netilmicin, amikacin and arbekacin were 66%, 68%, 52%, 38% and 1%, respectively. Gentamicin non-susceptibility rates were 4% and 91% in methicillin-susceptible and -resistant isolates, respectively. aac(6')-Ie-aph(2'')-Ia, aph(3')-IIIa and/or ant(4')-Ia were encountered in 125 (69%), 1 (0.5%) and 30 (16.6%) isolates, respectively. Forty-six (26%) isolates negative for AME genes were susceptible to all aminoglycosides. In contrast, 115 (92%), 91 (73%) and 66 (53%) of aac(6')-Ie-aph(2'')-Ia positive isolates were non-susceptible to gentamicin, netilmicin and amikacin, respectively. Only one isolate showed arbekacin resistance. However, aac(6')-Ie-aph(2'')-Ia positive isolates and isolates with gentamicin MIC 128 mg/L displayed a significant reduction in arbekacin inhibition zones.
Conclusions: A high prevalence of aminoglycoside resistance was detected and associated with methicillin resistance. Discrepancies between phenotypic and genetic detection of aminoglycoside resistance were discerned. Gentamicin was the preferred substrate for phenotypic detection of aac(6')-Ie-aph(2'')-Ia. Arbekacin showed favourable antibacterial activity even in aac(6')-Ie-aph(2'')-Ia-positive isolates. We suggest including arbekacin in future clinical trials of empirical treatment of late onset neonatal sepsis.
Keywords: arbekacin , aminoglycoside-modifying enzymes , methicillin resistance
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In many countries, the prevalence of aminoglycoside resistance among CoNS has increased.911 The main mechanism of aminoglycoside resistance is drug inactivation by aminoglycoside-modifying enzymes (AMEs) encoded within mobile genetic elements.1214 The following three AMEs are of particular significance among staphylococci since they modify and thereby inactivate the traditional aminoglycosides of therapeutic importance (Table 1): aminoglycoside-6'-N-acetyltransferase/2''-O-phosphoryltransferase [AAC(6')/APH(2'')], aminoglycoside-4'-O-nucleotidyltransferase I [ANT(4')-I] and aminoglycoside-3'-O-phosphoryltransferase III [APH(3')-III].1517 Variations in AME substrate specificity (Table 1) explain differences in antibacterial activity among the aminoglycosides.16 The bifunctional enzyme, AAC(6')/APH(2''), is the most frequently encountered AME in staphylococcal isolates and modifies to a different degree essentially all clinically available aminoglycosides, except streptomycin.1618 Arbekacin, currently used for neonates only in Japan,19,20 is stable against most AMEs and shows minimal inactivation by the bifunctional enzyme compared with other aminoglycosides.21,22
|
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
All data were collected from the tertiary care neonatal intensive care unit (NICU) at the National Hospital, Oslo. This NICU has an annual admission rate of approximately 800 patients. Baseline clinical and laboratory data including birth weight, gestational age and C-reactive protein (CRP) levels, were registered for all patients. Netilmicin was the only aminoglycoside used in the unit during the entire study period. The regional committee for medical research ethics approved the collection and analysis of patient data.
Bacterial strains
Between 1989 and 2000, a total of 180 CoNS blood culture isolates were collected from 148 neonates admitted to the unit. Blood cultures were collected from a peripheral vein after skin cleansing with a chlorhexidineethanol solution or from an intravascular catheter at the time of insertion. The cultures were obtained only when indicated by clinical signs of infection. Duplicate cultures were not routinely obtained. There are difficulties in the diagnosis of CoNS sepsis in neonates as usual practice in most neonatal units is to obtain only a single blood culture and because clinical signs of neonatal sepsis often are subtle. No uniformly accepted criteria exist to differentiate between invasive blood culture isolates and contaminants.23 In this study, we have used the criteria proposed by Stoll et al. and defined an invasive CoNS infection as a positive monomicrobial blood culture in a child older than 72 h combined with elevated CRP >10 mg/L within 2 days of blood culture and no other obvious alternative explanation for the clinical picture. All other CoNS blood isolates analysed, including cultures growing more than one organism, were considered to be contaminants.1,23 According to this classification, 85 isolates from 81 patients (four patients suffered from two separate episodes of CoNS sepsis) were considered as invasive and 95 isolates from 77 patients were considered as contaminants. Ten patients included in the study experienced both episodes classified as septicaemia as well as episodes where growth in blood culture was considered as a contaminant.
Identification and susceptibility testing
We identified all isolates to the species level by ID 32 Staph (bioMérieux, Marcy l'Étoile, France) according to the manufacturer's instructions. Gentamicin, tobramycin, netilmicin and amikacin MIC values were determined by Etest (AB Biodisk, Solna, Sweden). Isolates were categorized as susceptible (S), intermediate susceptible (I) and resistant (R) according to the clinical MIC breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST); gentamicin, tobramycin, netilmicin S2 mg/L and R > 4 mg/L, and amikacin S
8 mg/L and R > 16 mg/L.24 Moreover, for statistical analyses and group comparisons, we termed intermediate susceptible and resistant isolates as non-susceptible. The susceptibility to arbekacin (30 µg, Eiken Chemical Ltd, Japan) was determined according to the NCCLS standards for antimicrobial disc susceptibility tests.25 For comparison, a gentamicin disc (30 µg, AB Biodisk) was always used in the same run. No NCCLS or EUCAST breakpoints exist for arbekacin, but in Japan, using the NCCLS standard disc diffusion method, the following zone diameters are used for interpretation; R
13 mm; I 1417 mm; and S
18 mm (T. Ichiyanagi, Eiken Chemical Ltd, personal communication). In order to study co-resistance, we carried out Etests for oxacillin, fusidic acid and erythromycin. Phenotypic methicillin resistance was verified by detection of the mecA gene.26 The gentamicin- and methicillin-susceptible Staphylococcus epidermidis ATCC 12228 and the methicillin-resistant S. epidermidis ATCC 700586 were used as control strains.
PCR amplification of genes encoding aminoglycoside-modifying enzymes
Oligonucleotide primers for the three aminoglycoside resistance genes27 are listed in Table 1. Template DNA was prepared by dissolving a 1 µL loop of bacteria in 1 mL of TE buffer, centrifuged at 5000 rpm for 5 min, and the pellet resuspended in 100 µL of TE buffer. The suspension was boiled for 10 min before centrifugation at 5000 rpm for 5 min. The supernatant served as PCR template and PCRs were carried out as described previously28 with the following modification: thermal cycling consisted of an initial denaturing step of 1 min at 94°C; 30 cycles of 30 s at 95°C, 10 s at 58°C, and 30 s at 72°C; and a final extension step of 3 min at 72°C. Enterococcus faecium ATCC 51559 [possessing aac(6')-Ie-aph(2'')-Ia], Staphylococcus aureus N315 [possessing ant(4')-Ia] and Escherichia coli JM83 pUC18WaphA-3 [possessing aph(3')-IIIa] served as positive controls. S. aureus NCTC 8325 served as negative control. Primers targeting the 16S RNA gene were used as an internal control for each amplification reaction to identify potentially false-negative results.28 In addition, all PCRs were repeated when there was discordance between genotype and expected phenotype.16
Statistics
The MannWhitney U-test was used for comparison between groups of non-parametric data. Categorical analyses of non-susceptibility rates between invasive isolates and contaminants were carried out using the 2 test or Fisher's exact test, as appropriate. Categorical analyses of non-susceptibility rates between staphylococcal species were carried out using the
2 test with Bonferroni's correction for multiple adjustments. Trend analyses for aminoglycoside MIC values were assessed in a univariate linear model with year of obtained specimen as covariate. Trend analyses for genes encoding AMEs and the mecA gene were assessed in a binary logistic regression model. SPSS (11.0 for Windows) was used for all data analyses and a P value <0.05 was considered significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In total, 130 S. epidermidis and 50 other CoNS isolates were included. The distribution of species defined as invasive (I) isolates or contaminants (C) was as follows: S. epidermidis (I = 63, C = 67), Staphylococcus haemolyticus (I = 12, C = 7), Staphylococcus warneri (I = 4, C = 13), Staphylococcus hominis (I = 4, C = 6) and Staphylococcus capitis (I = 2, C = 2).
Table 2 shows aminoglycoside non-susceptibility rates in: (1) all isolates, (2) among different CoNS species and (3) among invasive isolates versus contaminants. We found significant (P < 0.02) differences in gentamicin, tobramycin, netilmicin and amikacin non-susceptibility rates between S. epidermidis, S. haemolyticus and the three other CoNS species (Table 2). In addition, invasive isolates showed significantly higher rates of non-susceptibility (P < 0.01) to gentamicin, tobramycin and netilmicin. The differences between invasive isolates and contaminants remained significant when analysing the 130 S. epidermidis isolates separately.
|
|
We specifically analysed isolates expressing high-level gentamicin resistance (HLGR), methicillin resistance or multidrug resistance. Fifty-seven isolates, 30 invasive and 27 contaminants, were defined as HLGR (MIC 128 mg/L). Among these 57 isolates, 15 and 33 isolates remained susceptible or intermediate susceptible to netilmicin and amikacin, respectively. Only 12 of 129 (9.3%) methicillin-resistant (MR) CoNS isolates were susceptible to gentamicin compared to 49 of 51 (96.1%) methicillin-susceptible (MS) CoNS isolates. However, a significant proportion of MR-CoNS was still susceptible to amikacin (47.3%) and netilmicin (27.9%). Fifty-four isolates, 29 invasive and 25 contaminants, were characterized as multidrug-resistant; oxacillin MIC
0.5 mg/L, erythromycin MIC
8 mg/L and fusidic acid MIC
1 mg/L. Five, 11 and 18 of these 54 isolates were susceptible to gentamicin, netilmicin and amikacin, respectively.
Phenotypic susceptibility to arbekacin
Only one isolate was resistant to arbekacin. This methicillin-resistant S. epidermidis was in addition highly resistant to all other aminoglycosides (MIC 256 mg/L), erythromycin (MIC
256 mg/L), clindamycin (MIC
256 mg/L), oxacillin (MIC
512 mg/L), rifampicin (MIC
256 mg/L) and fusidic acid (MIC
256 mg/L). The 179 other isolates showed an arbekacin (30 µg disc) zone diameter
19 mm (median 23 mm, range 1939 mm). Conversely, only 59 isolates revealed a gentamicin (30 µg disc) zone diameter
19 mm corresponding to gentamicin MIC values
0.25 mg/L. Reduced arbekacin inhibition zone diameters were more prevalent in invasive isolates compared with contaminants (P=0.026). S. epidermidis and S. haemolyticus also revealed reduced arbekacin inhibition zones compared with other CoNS (P < 0.001). In addition, as shown in Figure 2, HLGR isolates had reduced arbekacin inhibition zones compared with all other isolates (median 22 mm versus 24 mm, P < 0.001).
|
Table 3 shows the correlation between non-susceptibility to aminoglycosides and the presence of AME genes for all isolates. aac(6')-Ie-aph(2'')-Ia was encountered in 125 isolates (69.4%). All 19 S. haemolyticus isolates carried this gene. We found both aac(6')-Ie-aph(2'')-Ia and ant(4')-Ia in 22 isolates (12.2%). Eight isolates (4.4%) carried ant(4')-Ia only. No major difference in susceptibility pattern was found between gentamicin and tobramycin for aac(6')-Ie-aph(2'')-Ia positive isolates. ant(4')-Ia positive isolates were, as expected, more resistant to tobramycin than gentamicin (Tables 1 and 3). Only two isolates showed gentamicin borderline MIC values (MIC 24 mg/L), both carried aac(6')-Ie-aph(2'')-Ia. Seven out of nine tobramycin borderline isolates carried either aac(6')-Ie-aph(2'')-Ia (n=6) or ant(4')-Ia (n=1).
|
Forty-six isolates negative for all three AME genes were uniformly susceptible to all aminoglycosides tested (Table 3). All 46 isolates had gentamicin MIC values 0.25 mg/L. In addition, they displayed a similar susceptibility pattern for gentamicin and arbekacin using the disc diffusion method. The median zone diameter was 26 mm for both substrates; range arbekacin 2234 mm and gentamicin 2232 mm.
We found a close correlation between aminoglycoside non-susceptibility, detection of AME genes and methicillin resistance (Table 3). A similar correlation was seen among 54 multidrug-resistant isolates; 44 carried aac(6')-Ie-aph(2'')-Ia, 12 carried both ant(4')-Ia and aac(6')-Ie-aph(2'')-Ia and one isolate carried only ant(4')-Ia.
Trends in development of antibiotic resistance and resistance determinants
A significant trend towards lower MIC values for gentamicin (P=0.039) and netilmicin (P=0.041) was found during the study period. Analyses of invasive isolates revealed higher netilmicin MIC levels in the first 6 year period (n=47) compared with the second 6 year period (n=38); median MIC 16 mg/L and 4 mg/L, respectively (P < 0.001). For all other aminoglycosides, there were no significant trends in MIC levels during the study period. No significant trends were identified either in the prevalence of genes encoding AME or mecA. The proportion of mecA-positive isolates was 67.9%, 75.0%, 72.0% and 67.9% in the four consecutive 3 year periods of the study.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
All isolates with gentamicin MIC > 0.25 mg/L carried either aac(6')-Ie-aph(2'')-Ia, ant(4')-Ia, the combination of these two genes or aph(3')-IIIa. The concordances between gentamicin, tobramycin, netilmicin and amikacin non-susceptibility and the presence of aac(6')-Ie-aph(2'')-Ia gene were 92%, 91%, 73% and 52%, respectively.
However, a substantial proportion of isolates carrying aac(6')-Ie-aph(2'')-Ia, but still classified as susceptible to amikacin (28 out of 59) and netilmicin (17 out of 34), displayed MIC values of 8 and 2 mg/L, respectively. The relatively high MIC values in these strains are consistent with the expression of the aac(6')-Ie-aph(2'')-Ia gene, as aac(6')-Ie-aph(2'')-Ia-negative isolates showed much lower MIC values. Nevertheless, the distribution of MIC values (Figure 1) indicates, in agreement with other in vitro6,12,18,30 studies, that netilmicin and amikacin are more resistant to the substrate-inactivating effect of the AAC(6')/APH(2'') enzyme than gentamicin.
Aminoglycosides exhibit a concentration-dependent bactericidal effect in vivo whereas disc diffusion methods only reflect their bacteriostatic effect.31,32 A therapeutic peak-to-MIC ratio of 810 is considered optimal, but even lower ratios may inhibit bacterial growth.33,34 Recent neonatal high-dosage, extended-interval regimens report peak concentrations in the following range: gentamicin 610 mg/L,35,36 netilmicin 812 mg/L37 and amikacin 2232 mg/L.38,39 In our study, 65.5% of all isolates revealed gentamicin MIC values >4 mg/L, levels that most likely are limiting therapeutic efficacy. The interpretation of MIC data for netilmicin and amikacin is more controversial. A substantial proportion of aac(6')-Ie-aph(2'')-Ia-positive isolates revealed netilmicin and amikacin MIC values in a range where one might expect therapeutic efficacy, provided optimal peak concentration. According to Livermore et al.,16 gentamicin-resistant CoNS carrying the bifunctional enzyme are likely to remain susceptible to amikacin and netilmicin at British Society for Antimicrobial Chemotherapy (BSAC) breakpoints. In contrast, Courvalin claims that the bactericidal effect of netilmicin and amikacin is always abolished in Gram-positive cocci carrying the bifunctional enzyme and that these drugs should thus be considered inactive from a therapeutic point of view in spite of phenotypic susceptibility.32 Furthermore, in vitro studies show that a peak-to-MIC ratio of less than 4:1 may lead to bacterial regrowth and selection of resistant isolates33 and that gentamicin-susceptible S. epidermidis isolates carrying the aac(6')-Ie-aph(2'')-Ia gene change phenotype and turn resistant after sequential culturing.40 We believe that whether aminoglycoside treatment of phenotypically susceptible isolates carrying AME genes ultimately leads to therapeutic failure or not, warrants future studies. In the lack of these data, we still prefer interpretative reading with gentamicin as group representative for netilmicin and amikacin in clinical microbiological testing.32
Arbekacin is not modified by APH(3')-III or ANT(4')-I due to pharmacochemical modifications on the aminocyclitol ring.21 In addition, the bifunctional enzyme has a very low arbekacin inactivation rate compared with gentamicin.22 Traditional aminoglycosides are usually inactivated by AMEs. However, in vitro studies have shown that arbekacin may retain antibacterial activity despite being modified by AMEs.41,42 Arbekacin is thus considered to represent a new generation of aminoglycosides possessing a double-stage activity.42 In our study, arbekacin showed excellent in vitro activity, and the arbekacin inhibition zone diameters found in 179 of 180 isolates corresponded to gentamicin MIC values 0.25 mg/L. Despite this high prevalence of arbekacin susceptibility, aac(6')-Ie-aph(2'')-Ia-positive isolates and isolates with HLGR showed significantly reduced inhibition zones. This indicates, as previously described,14 that the bifunctional enzyme still has a certain inactivating effect on arbekacin. Only a few, small clinical studies have evaluated the clinical effect of arbekacin on gentamicin-resistant MRSA despite being extensively used for treatment of MRSA infections in Japan since 1990.20,4244 The clinical effect of arbekacin on invasive CoNS infections has not been evaluated in larger studies.
We detected ant(4')-Ia in 30 (17%) of our isolates; of which 28 and 22 in addition carried the mecA gene and the aac(6')-Ie-aph(2'')-Ia gene, respectively. In a recent Japanese study, a high prevalence (84.5%) of ant(4')-Ia in MRSA was presumed to be due to the adjacent locations of ant(4')-Ia and mecA.14 In a large European study, 32% of all CoNS carried ant(4')-Ia.15 A Korean study also found a high prevalence (27%) of ant(4')-Ia carriage among CoNS. In that study, however, ant(4')-Ia was not strongly associated with mecA, but frequently combined with aac(6)-Ie-aph(2'')-Ia carriage.13 The impact of ant(4')-Ia on the total aminoglycoside resistance level in this study was limited to higher rates of tobramycin resistance. However, it must be emphasized that these strains can easily be misclassified as susceptible when using gentamicin as a group representative for all aminoglycosides in antimicrobial testing of staphylococci.
Changes in the prevalence of aminoglycoside resistance occur slowly after long-term changes in the aminoglycoside selective pressure and the resistance mechanisms are related to the type of aminoglycoside used.17 As an example, the prevalence of arbekacin-resistant MRSA in Japan did not increase in the first 7 years after introduction of arbekacin.45 It was reassuring to observe a stable or even, for gentamicin and netilmicin, gradually declining aminoglycoside resistance rate during the 12 year study period. However, netilmicin was the only aminoglycoside used in this NICU since the latter half of the 1970s and the level of genotypic resistance due to aac(6')-Ie-aph(2'')-Ia was already high at the beginning of the study period.
NCCLS breakpoints25 for all aminoglycosides are higher compared with EUCAST.24 The chosen NCCLS breakpoint for susceptibility to netilmicin, 12 mg/L, is questionable as peak therapeutic concentrations in neonates infrequently exceed this value.25,37 From a pharmacokinetic point of view, EUCAST breakpoints for aminoglycosides seem more appropriate than NCCLS guidelines with regard to achievable peak concentrations in neonates. Moreover, even lower gentamicin and tobramycin breakpoints for CoNS (MIC 0.5 mg/L) would reflect the underlying genetic resistance mechanisms more precisely.
The mec complex, conferring methicillin resistance, is conveyed by a mobile chromosomal genetic element designated staphylococcal cassette chromosome mec (SCCmec). Plasmid pUB110, carrying ant(4')-Ia, is integrated in the SCCmec type II and integrated plasmids carrying transposon Tn4001, encoding aac(6')-Ie-aph(2'')-Ia,15 have been reported in SCCmec type IVc.46 These observations may explain the close correlation between aminoglycoside resistance and methicillin resistance found both in this and other studies.5,47
We conclude that 74% (134/180) of all blood culture isolates in this study carried an AME gene either alone or in combination. Gentamicin was the preferred substrate for phenotypic detection of aac(6')-Ie-aph(2'')-Ia. Among traditional aminoglycosides, netilmicin and especially amikacin showed the highest in vitro susceptibility rates. However, to our knowledge, no clinical trials have yet shown that this higher in vitro susceptibility actually translates into greater clinical efficacy in the treatment of CoNS infections. There is a paucity of data on arbekacin and CoNS infections. In this study, arbekacin showed excellent in vitro antibacterial activity in 99.4% of all isolates. Recent studies on arbekacin treatment of neonates show safety profiles similar to those of other aminoglycosides.20 We suggest including arbekacin in future clinical trials of empirical treatment of late onset neonatal sepsis to assess clinical efficacy and the subsequent need for vancomycin therapy.
![]() |
Acknowledgements |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 . Maayan-Metzger, A., Linder, N., Marom, D. et al. (2000). Clinical and laboratory impact of coagulase-negative staphylococci bacteremia in preterm infants. Acta Paediatrica 89, 6903.[CrossRef][ISI][Medline]
3
.
Isaacs, D. (2003). A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units. Archives of Disease in Childhood Fetal and Neonatal Edition 88, F89F93.
4
.
Isaacs, D. (2000). Rationing antibiotic use in neonatal units. Archives of Disease in Childhood Fetal and Neonatal Edition 82, F1F2.
5
.
De Giusti, M., Pacifico, L., Tufi, D. et al. (1999). Phenotypic detection of nosocomial mecA-positive coagulase-negative staphylococci from neonates. Journal of Antimicrobial Chemotherapy 44, 3518.
6 . Ronnestad, A., Abrahamsen, T. G., Gaustad, P. et al. (1999). Antibiotic susceptibility of blood culture isolates after nearly two decades with netilmicin and ampicillin in neonatal septicaemia. Acta Pathologica, Microbiologica et Immunologica Scandinavica 107, 25762.
7
.
Karlowicz, M. G., Buescher, E. S. & Surka, A. E. (2000). Fulminant late-onset sepsis in a neonatal intensive care unit, 19881997, and the impact of avoiding empiric vancomycin therapy. Pediatrics 106, 138790.
8 . Krediet, T. G., Jones, M. E., Gerards, L. J. et al. (1999). Clinical outcome of cephalothin versus vancomycin therapy in the treatment of coagulase-negative staphylococcal septicemia in neonates: relation to methicillin resistance and mecA gene carriage of blood isolates. Pediatrics 103, E29.[Medline]
9 . Schmitz, F. J., Theis, S., Fluit, A. C. et al. (1999). Antimicrobial susceptibility of coagulase-negative staphylococci isolated between 1991 and 1996 from a German university hospital. Clinical Microbiology and Infection 5, 4369.[CrossRef][Medline]
10 . Archer, G. L. & Climo, M. W. (1994). Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrobial Agents and Chemotherapy 38, 22317.[ISI][Medline]
11 . Bannerman, T. L., Rhoden, D. L., McAllister, S. K. et al. (1997). The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study. A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Archives of Ophthalmology 115, 35761.[Abstract]
12 . Busch-Sorensen, C., Frimodt-Moller, N., Miller, G. H. et al. (1996). Aminoglycoside resistance among Danish blood culture isolates of coagulase-negative staphylococci. Acta Pathologica, Microbiologica et Immunologica Scandinavica 104, 87380.
13 . Choi, S. M., Kim, S. H., Kim, H. J. et al. (2003). Multiplex PCR for the detection of genes encoding aminoglycoside modifying enzymes and methicillin resistance among Staphylococcus species. Journal of Korean Medical Science 18, 6316.[ISI][Medline]
14
.
Ida, T., Okamoto, R., Shimauchi, C. et al. (2001). Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. Journal of Clinical Microbiology 39, 311521.
15
.
Schmitz, F. J., Fluit, A. C., Gondolf, M. et al. (1999). The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. Journal of Antimicrobial Chemotherapy 43, 2539.
16 . Livermore, D. M., Winstanley, T. G. & Shannon, K. P. (2001). Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. Journal of Antimicrobial Chemotherapy 48, Suppl. 1, S87S102.[CrossRef]
17 . Miller, G. H., Sabatelli, F. J., Hare, R. S. et al. (1997). The most frequent aminoglycoside resistance mechanismschanges with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clinical Infectious Diseases 24, Suppl. 1, S46S62.[ISI][Medline]
18 . Udo, E. E. & Dashti, A. A. (2000). Detection of genes encoding aminoglycoside-modifying enzymes in staphylococci by polymerase chain reaction and dot blot hybridization. International Journal of Antimicrobial Agents 13, 2739.[CrossRef][ISI][Medline]
19 . Suzuki, K., Tanikawa, K. & Matsuzaki, T. (2003). Pharmacokinetics and dosing of arbekacin in preterm and term newborn infants. Pediatrics International 45, 1759.[CrossRef][ISI][Medline]
20 . Suzuki, K. (2003). Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Pediatrics International 45, 3016.[ISI][Medline]
21
.
Mingeot-Leclercq, M. P., Glupczynski, Y. & Tulkens, P. M. (1999). Aminoglycosides: activity and resistance. Antimicrobial Agents and Chemotherapy 43, 72737.
22 . Inoue, M., Nonoyama, M., Okamoto, R. et al. (1994). Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus. Drugs Under Experimental and Clinical Research 2339.
23 . Craft, A. & Finer, N. (2001). Nosocomial coagulase negative staphylococcal (CoNS) catheter-related sepsis in preterm infants: definition, diagnosis, prophylaxis, and prevention. Journal of Perinatology 21, 18692.[CrossRef][Medline]
24 . EUCAST clinical MIC breakpoints. [Online.] http://www.srga.org/eucastwt/MICTAB/MICaminoglycosides.html (8 September 2004, date last accessed).
25 . National Committee for Clinical Laboratory Standards. (2002) Performance Standards for Antimicrobial Susceptibility Testing12th Informational Supplement: Approved Standard M100-S12. NCCLS, Wayne, PA, USA.
26 . Predari, S. C., Ligozzi, M. & Fontana, R. (1991). Genotypic identification of methicillin-resistant coagulase-negative staphylococci by polymerase chain reaction. Antimicrobial Agents and Chemotherapy 35, 256873.[ISI][Medline]
27
.
Vakulenko, S. B., Donabedian, S. M., Voskresenskiy, A. M. et al. (2003). Multiplex PCR for detection of aminoglycoside resistance genes in enterococci. Antimicrobial Agents and Chemotherapy 47, 14236.
28 . Hanssen, A. M., Kjeldsen, G. & Sollid, J. U. (2004). Local variants of staphylococcal cassette chromosome mec in sporadic methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci: evidence of horizontal gene transfer? Antimicrobial Agents and Chemotherapy 48, 28396.[CrossRef]
29 . Tabe, Y., Nakamura, A., Oguri, T. et al. (1998). Molecular characterization of epidemic multiresistant Staphylococcus haemolyticus isolates. Diagnostic Microbiology and Infectious Disease 32, 17783.[CrossRef][ISI][Medline]
30 . Shore, K. & Morris, A. (2002). Amikacin as a replacement aminoglycoside for netilmicin for coagulase-negative staphylococcal sepsis in neonates. New Zealand Medical Journal 115, U216.[Medline]
31 . Miron, D. (2001). Once daily dosing of gentamicin in infants and children. Pediatric Infectious Disease Journal 20, 116973.[CrossRef][ISI][Medline]
32 . Courvalin, P. (1996). Interpretive reading of in vitro antibiotic susceptibility tests (the antibiogramme). Clinical Microbiology and Infection 2, Suppl. 1, S26S34.[Medline]
33 . Blaser, J., Stone, B. B., Groner, M. C. et al. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 31, 105460.[ISI][Medline]
34 . Moore, R. D., Lietman, P. S. & Smith, C. R. (1987). Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 155, 939.[Medline]
35
.
Lundergan, F. S., Glasscock, G. F., Kim, E. H. et al. (1999). Once-daily gentamicin dosing in newborn infants. Pediatrics 103, 122834.
36 . Rastogi, A., Agarwal, G., Pyati, S. et al. (2002). Comparison of two gentamicin dosing schedules in very low birth weight infants. Pediatric Infectious Disease Journal 21, 23440.[CrossRef][ISI][Medline]
37 . Klingenberg, C., Smabrekke, L., Lier, T. et al. (2004). Validation of a simplified netilmicin dosage regimen in infants. Scandinavian Journal of Infectious Diseases 36, 4749.[CrossRef][ISI][Medline]
38 . Langhendries, J. P., Battisti, O., Bertrand, J. M. et al. (1998). Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biology of the Neonate 74, 35162.[CrossRef][ISI][Medline]
39 . Berger, A., Kretzer, V., Gludovatz, P. et al. (2004). Evaluation of an amikacin loading dose for nosocomial infections in very low birthweight infants. Acta Paediatrica 93, 35660.[CrossRef][ISI][Medline]
40
.
Martineau, F., Picard, F. J., Grenier, L. et al. (2000). Multiplex PCR assays for the detection of clinically relevant antibiotic resistance genes in staphylococci isolated from patients infected after cardiac surgery. The ESPRIT Trial. Journal of Antimicrobial Chemotherapy 46, 52734.
41 . Hotta, K., Zhu, C. B., Ogata, T. et al. (1996). Enzymatic 2'-N-acetylation of arbekacin and antibiotic activity of its product. Journal of Antibiotics 49, 45864.[ISI][Medline]
42 . Kondo, S. & Hotta, K. (1999). Semisynthetic aminoglycoside antibiotics: development and enzymatic modifications. Journal of Infection and Chemotherapy 5, 19.[Medline]
43 . Hayashi, I., Inoue, M. & Hashimoto, H. (1994). Nationwide investigation in Japan on the efficacy of arbekacin in methicillin-resistant Staphylococcus aureus infections. Drugs Under Experimental and Clinical Research 20, 22532.[ISI][Medline]
44 . Fujii, R., Fujita, K., Sakata, Y. et al. (1994). Clinical studies of arbekacin sulfate in the pediatric field. Japanese Journal of Antibiotics 47, 5783.[Medline]
45 . Deguchi, K., Suzuki, Y., Ishihara, R. et al. (1997). Antimicrobial activities of arbekacin against methicillin-resistant Staphylococcus aureus. Japanese Journal of Antibiotics 50, 111.[Medline]
46 . Ito, T., Okuma, K., Ma, X. X. et al. (2003). Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC. Drug Resistance Updates 6, 4152.[CrossRef][ISI][Medline]
47 . Diekema, D. J., Pfaller, M. A., Schmitz, F. J. et al. (2001). Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 19971999. Clinical Infectious Diseases 32, Suppl. 2, S11432.[CrossRef][ISI][Medline]
|